Immunovant Inc
IMVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.71B
Close$
$4.94
86.9% downside
Current Fair Value
86.9% downsideOvervalued by 86.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.71 Billion |
|---|---|
| Enterprise Value | $6.91 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.77 |
| Beta | 0.81 |
| Outstanding Shares | 205,545,373 |
Return
| Return on Equity | -73.19% |
|---|---|
| Return on Assets | -63.13% |
| Return on Invested Capital | -60.45% |
Valuation & Multiples
| P/E Ratio | -13.25 |
|---|---|
| PEG | -49 |
| Price to Sales | - |
| Price to Book Ratio | 12.55 |
| Enterprise Value to Revenue | 974.4 |
| Enterprise Value to EBIT | -15.55 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
$7.09 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1536▲ 4.90% |
|---|---|
| Total Calls | 1,801,100▼ 28.30% |
| Total Puts | 276,600▲ 5.25% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 54.04%▼ 6.59% |
|---|---|
| Total Invested | $4.28B▲ 55.73% |
| Investors Holding | 240▲ 14.00% |
ESG Score
No data